EIF2B Activator BMS-986419 / EVT-8683 Prevents Integrated Stress Response and Protects from Neurological Decline in a Vanishing White Matter Disease Model (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR172.03 / T7; Pres time: Nov 16, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "With 18 weeks of once-daily dosing, BMS-986419 / EVT-8683 fully normalized ISR and body weight and completely prevented astrogliosis, microgliosis, neurodegeneration, weight loss, and motor deficits. Together, these data identify BMS-986419 / EVT-8683 as a brain-penetrant ISR inhibitor with potential to treat VWMD and other neurological diseases driven by chronic ISR activation."
CNS Disorders • Tauopathies And Synucleinopathies • EIF2B4
|
|
D. MENSCHING1; A. GARCIA DIAZ BARRIGA1; N. C. CARTY1; M. HERMANN2; T. KRÖCHER1; E. STRERATH1; M. GRUEN1; K. KOLLMANN2; T. SAMATOV2; B. SEIP2; A. LUCAS4; F. DEGLAVE5; E. ERDOCIAIN5; C. BROWN4; D. WALTER4; M. GEMKOW1; R. B. BOYANAPALLI6; K. J. RHODES7; R. J. HARGREAVES7; R. KUHN3; Y. RUDHARD1
|